

Ref: BHL/ STEX 24/ 2025-26

Date: July 28, 2025

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Scrip Code: 539872	National Stock Exchange of India Limited 5 th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Symbol: BAJAJHCARE
--	---

Dear Sir/Madam,

Sub: Press Release for the Quarter ended June 30, 2025

In terms of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed herewith Press Release for the quarter ended June 30, 2025.

Kindly take the same on record.

Thanking you.

Yours faithfully,

**For and on behalf of Board of Directors
of Bajaj Healthcare Limited**

**Monica Tanwar
Company Secretary & Compliance Officer**

Encl: As above



Investor Release

Bajaj Healthcare Delivers Strong Q1 FY26 Results

Accelerates Profitability in Q1 FY26 with 66% PAT Growth, 12.5% Revenue Uptick

Mumbai, 28th July 2025: Bajaj Healthcare Limited, one of the leading manufacturers of APIs, Intermediates and Formulations, announced its financial results for the quarter ended 30th June 2025.

Key Financial Highlights

Particulars (Rs. Mn)	Q1 FY26	Q1 FY25	Y-o-Y	Q4 FY25	Q-o-Q
Revenue from Operations	1,488.4	1,322.5	12.5%	1,544.7	-3.6%
EBITDA	253.9	253.6	0.1%	253.3	0.2%
EBITDA Margin (%)	17.0%	19.1%		15.1%	
PAT from Cont. Operations	121.7	80.3	51.7%	115.9	5.0%
PAT Margin (Cont. Operations)	8.1%	6.0%		6.9%	
PAT from Disc. Operations	-3.4	-8.9		-4.2	
Profit for the period	118.3	71.3	65.9%	111.8	5.9%
Profit for the period(%)	7.9%	5.4%		6.7%	

Revenue Breakup

Particulars (Rs. Mn)	Q1 FY26	Q1 FY25	Y-o-Y	Q4 FY25	Q-o-Q
API (Domestic)	726.0	842.2	-13.8%	893.3	-18.7%
API (Exports)	521.9	309.9	68.4%	407.5	28.1%
Formulations	240.5	170.4	41.1%	243.8	-1.4%

Commenting on the Results, Mr. Anil Jain – Managing Director said,

“Q1 FY26 marks a strong and promising start to the new fiscal year for Bajaj Healthcare, despite a challenging pricing environment in certain segments. Revenue from operations rose 12.5% year-on-year to ₹1,488.4 Mn, while PAT grew by 66% to ₹118.3 Mn, reflecting improved profitability and sharper execution across business segments. EBITDA remained steady at ₹253.9 million, with margins improving sequentially to 17.0% from 15.1%, reflecting better product mix and improved operating leverage, even amidst input cost pressures.

Segment-wise, our API export business delivered standout growth of 68.4% YoY, supported by growing demand in regulated markets and the ramp-up of commercial CDMO supplies. Formulations saw 41.1% year-on-year growth, led by deeper market penetration and new strategic partnerships. Due to pricing headwinds in the domestic API segment, the company has strategically realigned its portfolio towards value-added exports and differentiated molecules to reinforce growth and profitability.



....We are pleased to report that during the quarter, we received three new CEP approvals and one ASMF approval from European regulatory authority, further strengthening our position in regulated EU/UK markets. Following product approvals, validation batch supplies have commenced for a few molecules under CDMO agreements. In parallel, five DMFs were filed with the UK MHRA to enable future commercial supply and regulatory compliance. To date, we have filed a total of nine CEPs, out of which seven have been approved. Furthermore, four additional CEP filings are in process.



Our CNS portfolio continues to evolve with notable regulatory developments. Cenobamate has received a positive recommendation from the Subject Expert Committee (SEC) and is currently awaiting final DCGI approval to initiate Phase III trials. For Magtein®, validation batches are underway, with commercial launch targeted in Q3. These developments mark important steps toward expanding our product pipeline.

Backward integration continues to be a cornerstone of our strategy, especially in supporting scale-up across CDMO and formulation segment. Export contribution rose to 35% of total revenue, up from 23% last year, reflecting stronger API demand and deeper access to global markets. We remain firmly on course to build a value-driven, innovation-led growth engine across APIs, formulations, and CDMO.”

About Bajaj Healthcare Ltd:

Bajaj Healthcare Limited a leading Manufacturer of APIs, Intermediates and Formulations. Established in the year 1993. It specializes in manufacturing of intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.

Contact Details:

Bajaj Healthcare Ltd	Investor Relations: MUFG Intime India Pvt. Ltd.
	
CIN: L99999MH1993PLC072892	Name: Ms. Prachi Ambre/ Mr. Irfan Raeen
Name: Mr. Anil Jain, MD	Email: prachi.ambre@in.mpms.mufg.com / irfan.raeen@in.mpms.mufg.com
Email: investors@bajajhealth.com	Meeting Request Link – Click Here



Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.